preloader
Clever-Access
JCA MANAGEMENT & EU HTA SERVICES

The Pioneer in JCA Management

The Joint Clinical Assessment has changed how medicines reach patients across Europe. Clever-Access was among the very first consultancies to support a product through the JCA process end to end — and we've built that experience into EUREKA, our roadmap for Health Technology Developers navigating JCA and EU HTA requirements from early development to launch.

ツール&ソリューション

Why Clever-Access and EUREKA

First-mover experience, deep training expertise and an active role in shaping the EU HTA ecosystem.

1 of the first

products supported through JCA — full package, strategy to submission

1 sessions

dedicated EU HTA training, customised to pharma companies' needs

+ 1 publications

on EU HTA and JCA, including posters presented at ISPOR Europe

+ 1 projects

delivered across JCA-related engagements
for HTDs of all sizes
OUR ROADMAP

予測。連携。創出。成功。EUREKA!

EUREKA — the EUropean Roadmap for Empowered market Access — is our structured, strategic evidence-based roadmap guiding HTDs through the JCA process, from early development to launch.

01 Strategic Decision Making 
From early development to launch, at every key milestone.

02 Evidence Optimisation 
Focuses investment on the game changer data  for JCA.

03 Full Alignment 
Meets EU and national requirements alongside internal goals.

key elements

Key elements of EUREKA

Five integrated workstreams that anticipate JCA scoping and keep strategy on track.

PICO戦略:

HTDの戦略的フォーカスを維持しながら、JCA視点を予測し対応するための体系的な3段階アプローチ:

PICO予測:PICO調査の結果を反映した加盟国の期待値を予測する。

PICOの統合:リストを管理しやすく、JCAに関連する範囲に絞り込む。

PICO優先順位付け:EUおよび各国への申請における戦略的重点分野を定める。

プリカーサーSLR

随時更新されるエビデンス・データベースは、PICOスコーピングの段階での変化に対応し、HTDが常に一歩先んじることを可能にします。

エビデンス創出計画

臨床およびリアルワールドのデータ戦略をPICOの優先事項と整合させ、既存データ、新たなエビデンス創出の機会、およびJCAの期待を活用する。

間接比較(ITC)

比較対象とのギャップを解消し、臨床的価値に関する説明を強化するために統合された、堅牢で方法論的に健全なITC。

JCA向け申請資料作成

JCA申請を成功させ、合理化するために調整された、戦略とエビデンスのパッケージ全体をまとめた、一貫性のある説得力のある書類。

key elements

Key elements of EUREKA

Five integrated workstreams that anticipate JCA scoping and keep strategy on track.

PICO戦略:

Three-step approach — prediction, consolidation, prioritisation — to anticipate JCA scoping.

プリカーサーSLR

A living evidence database that adapts as the PICO scoping phase evolves.

エビデンス創出計画

Aligns clinical and RWE strategies with PICO priorities and JCA expectations.

間接比較(ITC)

Robust indirect treatment comparisons that close comparator gaps matching requirements.

JCA向け申請資料作成

A cohesive compliant dossier bringing the full strategy and evidence together.

key elements

Full-Service JCA & EU-HTA Support

Beyond EUREKA, our team supports every stage of the JCA and EU HTA lifecycle.

  • Early HTA and JCA advice, from portfolio prioritisation to launch sequencing
  • Managing responses and interaction with the HTA secretariat
  • Representing and defending clients before JCA assessors
  • Mock HTA/JCA panels to pressure-test dossiers before submission
  • Systematic literature reviews (SLRs) and indirect treatment comparisons
  • Dossier development, review and quality control
  • Post-submission support and ongoing engagement with HTA bodies
  • Affiliate training and support responding to payer/HTA objections
OUR PROGRAMMES

Training & Thought Leadership 

Clever-Access experts are the key faculty behind two flagship EU HTA programmes.

 

EU HTA Masterclass 

Enrollment open · Start October 5

An in-depth programme preparing professionals to lead JCA and EU HTA strategy, led by Clever-Access’s own experts, including Prof. Mondher Toumi.

IMAUD Online Market Access Course

Enrollment open · Start November 2

The IMAUD programme continues to train the next generation of market access professionals, with Clever-Access expertise at its core.

Ready to navigate JCA with confidence?

Whatever stage your product is at, our team can help you anticipate JCA requirements, build the right evidence and secure timely market access.